4165 related articles for article (PubMed ID: 538574)
1. Increased immunogenicity of B16 melanoma clones selected for their ability to metastasize from a heterogeneous primary tumor.
Steele GD; Richie JP; Wang BS; Mannick JA; Wilson RE
Surg Forum; 1979; 30():132-3. PubMed ID: 538574
[No Abstract] [Full Text] [Related]
2. [Cytotoxic immunity indices of melanoma B16 growth in mice].
Korosteleva TA; Veresova OV
Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
Celik C; Lewis DA; Goldrosen MH
Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases.
Poste G; Doll J; Brown AE; Tzeng J; Zeidman I
Cancer Res; 1982 Jul; 42(7):2770-8. PubMed ID: 7083167
[TBL] [Abstract][Full Text] [Related]
5. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
Hawkins WG; Gold JS; Blachere NE; Bowne WB; Hoos A; Lewis JJ; Houghton AN
J Surg Res; 2002 Feb; 102(2):137-43. PubMed ID: 11796010
[TBL] [Abstract][Full Text] [Related]
6. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
Stackpole CW; Demsey A
Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
[TBL] [Abstract][Full Text] [Related]
7. Antigenic differences among B16 melanoma variants selected for their differing abilities to metastasize: a possible mechanism for effective adjuvant immunotherapy.
Steele G; Wang BS; Ghavamzadah G; Fallon M; Richie J; Wilson RE; Mannick JA
J Surg Oncol; 1980; 15(1):71-83. PubMed ID: 6158632
[No Abstract] [Full Text] [Related]
8. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects and parallel in vitro cytotoxicity of splenocytes harvested from treated or control C57BL/6J mice after adjuvant immunotherapy of pulmonary metastases using xenogeneic RNA specific to B16 murine melanoma.
Wang BS; Steele G; Mannick JA; Fallon M; Onikul SR
Cancer Res; 1979 May; 39(5):1702-7. PubMed ID: 427807
[No Abstract] [Full Text] [Related]
10. Biological behavior of malignant melanoma cells correlated to their survival in vivo.
Fidler IJ
Cancer Res; 1975 Jan; 35(1):218-24. PubMed ID: 1109790
[TBL] [Abstract][Full Text] [Related]
11. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
LeGrue SJ; Hearn DR
Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
13. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP
J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209
[TBL] [Abstract][Full Text] [Related]
14. Relationship of antigenicity of melanoma cells grown in 5-bromodeoxyuridine to reduced tumorigenicity.
Silagi S; Newcomb EW; Weksler ME
Cancer Res; 1974 Jan; 34(1):100-4. PubMed ID: 4358536
[No Abstract] [Full Text] [Related]
15. Differences in cell density associated with differences in lung-colonizing ability of B16 melanoma cells.
Baniyash M; Netanel T; Witz IP
Cancer Res; 1981 Feb; 41(2):433-7. PubMed ID: 7448787
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in growth inhibition by beta-trans-retinoic acid of metastatic B16 melanoma clones and in vivo-selected cell variant lines.
Lotan R; Nicolson GL
Cancer Res; 1979 Dec; 39(12):4767-71. PubMed ID: 498105
[No Abstract] [Full Text] [Related]
17. Development of host immunity to phenotypically diverse B16 melanoma clones. Implications for tumor growth and metastasis.
Stackpole CW; Alterman AL; Braverman S; Rappaport I
Invasion Metastasis; 1987; 7(6):346-66. PubMed ID: 3436737
[TBL] [Abstract][Full Text] [Related]
18. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
19. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.
Fidler IJ; Gersten DM; Budmen MB
Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082
[TBL] [Abstract][Full Text] [Related]
20. Role of polymorphonuclear leukocytes in the pulmonary clearance of arrested cancer cells.
Glaves D
Invasion Metastasis; 1983; 3(3):160-73. PubMed ID: 6329986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
